Clinical and laboratory values for subjects over time by D3 dose group.

*Significantly different from baseline within the dose group at p**p≤0.01***pa n = 49, Bioavailable 25(OH)D and DBP at baseline (24 at 4000 and 25 at 7000IU/d D3) and n = 51 12 weeks visit (26 at 4000 and 25 at 7000IU/d D3)b n = 56, CD4 baseline and 12 weeks visit (27 at 4000 and 29 at 7000IU/d D3)c n = 41, RNA viral load analysis baseline and 12-week visit (20 at 4000 and 21 at 7000IU/d vit D3)—as these 41 subjects had VL run at the same laboratory both times—baseline and 12 weeksd n = 40 subjects CD4, cluster of differentiation; PTH, parathyroid hormone; DBP, vitamin D binding protein.Clinical and laboratory values for subjects over time by D3 dose group.*在给药组内与基线相比存在显著差异（p≤0.01） a 样本量n=49，对应基线时的生物可利用性25羟维生素D（Bioavailable 25(OH)D）与维生素D结合蛋白（DBP, vitamin D binding protein）数据（4000IU/d组24例，7000IU/d D3组25例）；另有n=51例完成12周随访访视，对应同指标数据（4000IU/d组26例，7000IU/d D3组25例） b 样本量n=56，对应基线及12周随访访视时的CD4细胞数据（4000IU/d组27例，7000IU/d D3组29例） c 样本量n=41，对应基线及12周随访访视时的RNA病毒载量分析数据（4000IU/d组20例，7000IU/d维生素D3组21例）；因该41例受试者两次检测均在同一实验室完成病毒载量（VL, viral load）检测 d 样本量n=40的受试者数据对应CD4细胞（cluster of differentiation，分化簇）；相关术语说明：PTH为甲状旁腺激素（parathyroid hormone），DBP为维生素D结合蛋白（vitamin D binding protein） 按维生素D3给药剂量分组的受试者随时间变化的临床与实验室检测指标。